Full Report

Know the Business

Figures converted from GBP at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

Elixirr is a senior-led "challenger" consultancy that bills experienced Partners at premium rates and grows by stretching them, hiring more, and bolting on US/Nordic specialty firms. The 30% adjusted EBITDA margin is the giveaway — it is roughly double Accenture's and triple ICF's, and exists because the firm refuses the traditional pyramid that delivers analysts cheap and bills them expensive. The market is most likely overestimating how much of the FY25 34% revenue growth is durable — only 15% was organic — and underestimating how much equity dilution and contingent consideration is quietly funding the headline.

1. How This Business Actually Works

The product is one experienced Partner, sold by the day, on a fixed-outcome contract — supported by a small team of consultants, data engineers, and increasingly, AI tooling. There is no army of new graduates being marked up 5x; that is the entire model in one sentence.

The economic engine has three throttles. First, revenue per Partner — a Partner sold full-time at premium rates generates $5.9M a year, double the $4.1M at IPO, and this has compounded faster than headcount. Second, the Partner count — 34 client-facing Partners (up from 27 in FY24), grown by promoting Principals (3 in FY25), poaching laterals (2 in FY25), and by acquiring boutique firms with embedded senior teams (6 came with TRC). Third, cross-sell into the installed base — gold clients (those generating over $1.3M) rose from 27 to 34, and cross-capability revenue hit $50M, or 25% of the group, up from 17% the year before.

Both levers have moved every year since IPO. That is rare in services — most consultancies grow either by adding bodies (margin-dilutive) or by raising rates (capacity-capped). Elixirr has done both at once because the equity-participation model — 84% of consultants enrolled — recruits and retains people willing to take ownership over compensation, and AI tooling (45 internal agents, proposals built in 10% of prior time) absorbs the work the new graduates would have done.

The cost of the engine is hidden in two places investors should track. Stock-based compensation ran $6.3M in FY25 — 3.2% of revenue, up from 2.3% in FY21. That is the price of the equity model and it grows roughly linearly with headcount. Contingent consideration sits at $56.8M on the balance sheet — earnouts owed to acquired-firm sellers — versus $13.1M a year ago. Each acquisition is partly self-financing (sellers earn out only if their unit performs), but the cumulative liability has more than quadrupled.

2. The Playing Field

Elixirr is a fly in a room of elephants — its margin is the highest in the peer set, its scale the smallest, and the gap on both axes is enormous.

Revenue and market cap shown in $M for cross-currency comparability. Elixirr reports in GBP; figures converted at FY25 year-end FX (1.3466).

Three things stand out. ELIX is the only peer in the upper-right quadrant — high growth and high margin. The big peers (ACN, BAH) earn lower margins because they leverage juniors and absorb a far larger overhead structure; ELIX skips both. The mid-size US specialty firms (FCN, HURN, ICFI) operate at margins broadly comparable to ACN, which suggests it is not size that compresses margin — it is delivery model.

The gap on multiples is narrower than the gap on operations. Accenture is at ~12.5x EV/EBITDA on its FY25 close — and has de-rated meaningfully since (the stock has lost roughly 40% of its value over the past year on AI-substitution fears). ELIX at 11.5x is broadly in line with the big-cap peer despite triple-the-growth and double-the-margin. The market is essentially saying: "we do not believe the 30% margin and 34% growth are fully sustainable through-cycle." That is the bet to underwrite.

3. Is This Business Cyclical?

Consulting is a discretionary spend item — when corporate budgets tighten, transformation projects are the first to be shelved. So yes, the industry is cyclical, but Elixirr's reported numbers do not show it because the company has been in capture phase, growing through whatever cycle the market has thrown at it.

Adjusted EBITDA margin held a 24–30% band across the same period: 24% in FY20, 27% in FY22, 28% in FY24, 29.6% in FY25. The statutory operating margin reads lower (19.9% in FY25) because acquisition-related intangible amortisation now runs ~$9.7M a year — useful for cash flow analysis, misleading if compared to peers who do not amortise.

The cycle hits four places in this business. Demand: large transformation programmes get postponed when CFOs hold the purse strings — the first signal is end-of-programme attrition without replacement ($19.3M of attrition in FY25, fully absorbed by $42M of expansion). Pricing: rate cards hold up better than utilisation, so margins fall before they crater — Elixirr's adjusted EBITDA margin has held a 28–30% band through three different macro environments (post-COVID 2021, rate-shock 2023, AI-disruption 2024–25). Utilisation: the dangerous metric, not disclosed publicly — when Partners cannot fill their book, the senior-led model becomes a fixed-cost trap. Working capital: clients stretch payables in a slowdown, and FY25 already showed the early sign — receivables rose 46% as revenue rose 34%, dragging FCF growth (+11%) well below EBITDA growth (+42%).

The honest assessment: ELIX has never been tested by a real consulting recession. It IPO'd in July 2020 into a post-COVID rebound, expanded through the rate cycle on cross-sell and acquisition tailwinds, and is now riding the AI demand wave. The first true through-cycle test will reveal whether the senior-led model is anti-fragile (Partners absorb downside via lower variable comp) or vulnerable (Partners walk if equity cannot vest).

4. The Metrics That Actually Matter

Forget P/E and forget revenue growth in isolation. Five operating metrics tell you whether the engine is running.

Cross-sell at 25% is the most underrated number. It says the acquisitions are knitting together — TRC clients are buying Elixirr capability, Hypothesis is selling research into Elixirr accounts. If cross-sell stalls or reverses, the firm is just buying revenue at 6–8x EBITDA and then re-selling it at the same multiple in its own stock.

Free cash conversion at 70% is the early warning sign nobody talks about. Operating cash flow grew 12% on EBITDA growth of 42% — most of the gap is one big working-capital build, but if it persists into FY26 it implies either client stretch (cyclical) or aggressive revenue recognition (idiosyncratic). Either is bad.

5. What Is This Business Worth?

Value is mostly determined by earnings power × reinvestment runway, not by assets, segments, or hidden stakes. Tangible book value is negative $74M (intangibles are 79% of assets), so book is meaningless. There is no listed subsidiary, no holding-company discount to unwind, no separable business worth carving out. This is one engine, and the question is what flow rate it can sustain.

ELIX trades at roughly 22x trailing P/E and 11.5x EV/EBITDA on FY25 numbers — broadly in line with Accenture (21x P/E, 12.5x EV/EBITDA) and well below Huron (30x P/E). The right framing is not "is the multiple cheap or expensive" but "what part of the next three years' growth is in the price." If you believe the firm can sustain 12%+ organic growth and 28%+ EBITDA margin through a real consulting recession, the multiple looks defensive. If you think margins compress to peer levels in any meaningful slowdown, the multiple looks rich because earnings would re-rate in both directions.

A SOTP lens is not appropriate here. There are no separable parts disclosed — the acquired entities (TRC, Kvadrant, Hypothesis, Insigniam, iOLAP, Coast Digital) are operationally integrated into the Group, share clients, and cross-sell. Disaggregating them is artificial.

6. What I'd Tell a Young Analyst

Watch four things, ignore everything else.

Revenue per Partner. It has gone from $4.1M to $5.9M in five years on the back of pricing, mix, and AI-augmented productivity. If it stops compounding at 5%+, the model has hit a ceiling and you are now paying a growth multiple for a flat-productivity business. This is the single most important leading indicator.

Organic vs total growth. FY25's headline 34% is misleading — half of it is the wrap-around of Hypothesis (FY24 deal) and the September TRC consolidation. Strip those out, organic was 15.3%. Track this number quarterly. The day organic falls below 10% while the firm is still buying companies, you have a roll-up problem.

Contingent consideration as % of equity. $57M sits on the balance sheet against $192M of equity — almost 30%. Each earn-out paid is a real cash outflow that does not show up in EBITDA. Watch the cash payments line in financing flows; the headline FCF understates the full reinvestment cost.

The AI claim. "AI revenue grew 260%" sounds compelling but it is from a tiny base. The honest test is whether AI work shows up as margin expansion (Elixirr captures the productivity gain) or margin compression (clients pay less for AI-assisted work). FY25 margin expanded — give that one more year before declaring victory.

Two things the market may be missing in either direction. The bull case nobody underwrites: Elixirr is the rare consultancy without a junior pyramid to defend, so AI substitution is asymmetric upside, not downside. The bear case nobody flags: when the consulting cycle finally turns, Partners with vested equity options and no client demand have an outside option (start their own boutique, or take their book to McKinsey). The equity model that recruits in good times can disperse the firm in bad ones.

The thesis-changers are simple: organic growth dropping below 10% while M&A continues; EBITDA margin breaking 25% on the downside; revenue per Partner flatlining for two consecutive years; or contingent consideration getting settled at 100% without proportional revenue lift. Any one of those would force a re-underwrite.

Figures converted from GBP at historical FX rates — see data/company.json.fx_rates for the rate table. Ratios, margins, and multiples are unitless and unchanged.

The Numbers

Elixirr is a hyper-growth UK-listed challenger consultancy that has compounded revenue at roughly 38% per year since IPO, runs nearly zero capex, converts more than 100% of net income into operating cash, and earns mid-teens returns on equity — yet the market prices it like a slowing professional-services firm, with a forward P/E of about 20x and EV/EBITDA near 11x. The single metric most likely to rerate or derate the stock is the operating margin: it peaked at 26.3% in FY2023 and has compressed by roughly 640 basis points to 19.9% in FY2025 as scaling costs, share-based compensation and integration of the Hypothesis Group acquisition bite. Whether margins stabilise above 20% (consensus thesis) or drift below it (risk case) decides the next 30%.

Snapshot

Consensus 12-month price target sits at $14.30 (range $13.90–$16.82 across four covering brokers); the stock at $9.85 implies roughly 45% upside before any rerating of the multiple.

---

Quality scorecard — is this a well-run business?

The cash machine works: 142% average FCF-to-net-income conversion over five years, capex under 0.2% of revenue, and an unleveraged balance sheet until FY2025. The blemishes are the goodwill build and a 640-basis-point margin slide from the FY2023 peak.

---

Revenue and earnings power — the post-IPO record

Revenue has scaled roughly 5x in five years — an exceptional pace for any business model, but particularly for a people-business where headcount has to track demand. The operating-margin chart is the more interesting one: peak profitability hit in FY2023, then unwound. The market is now debating whether that was a one-time mix windfall or a structural ceiling Elixirr can climb back toward.

H2-2025 reveals the margin-compression problem in detail: revenue grew 34% year on year but operating income grew only 21%. The operating-leverage thesis is stalling at exactly the moment Elixirr is most aggressively integrating Hypothesis.

---

Cash generation — are the earnings real?

Cash conversion is the clean story. Trailing five-year FCF / net income averages roughly 142% — a function of (a) working-capital release as deferred consideration washes through, (b) D&A from acquired intangibles flattering accounting income, and (c) genuinely tiny capex. There is essentially no gap between OCF and FCF because Elixirr does not own meaningful PP&E.

The one caveat: in FY2023 the conversion ratio dipped to 97% as receivables built. Elixirr has growing days-sales-outstanding (receivables $37.1M on $201.5M revenue = 67 days, up from 50 in FY2022). Worth watching if it widens further.

---

Capital allocation — discipline under acquisition mania

Three observations. One, total deployment in FY2025 ($131M across dividends, buybacks, M&A and debt service) exceeded operating cash flow of $44M — Elixirr funded the gap by issuing $80.8M of new debt to acquire Hypothesis Group. Two, buybacks have ramped six-fold from FY2021 levels even as the share count has crept higher, so management is offsetting employee-equity dilution rather than shrinking the float. Three, the dividend has grown every year and now consumes 43% of net income — sustainable but no longer trivial.

Share-based comp has nearly doubled from 1.6% to 3.2% of revenue in three years. Buybacks at this pace barely keep pace with dilution — the FY2025 buyback of $27.9M consumed roughly the same value as the $6.4M of SBC granted plus the equity issued for partner compensation.

---

Balance sheet — flexibility just narrowed sharply

Elixirr was net-cash for five consecutive years. FY2025 changed that: an $80.8M debt issuance to fund Hypothesis acquisition flipped the balance sheet to net debt of $38M, with leverage at 0.77x EBITDA. That is comfortable in absolute terms — a consultancy generating $44M of FCF can repay it in a year — but the direction of travel matters. Cash on the balance sheet has fallen from $42.9M (FY2021) to $6.8M, leaving little dry powder for the next acquisition without further debt or equity issuance.

The refinancing risk is small ($14.3M current portion); the optionality cost is larger.

---

Returns on capital — the engine, mid-cycle

ROIC peaked at 18.3% in FY2022 and now sits at 12.9% — a meaningful step-down driven by capital base expansion (acquisitions inflating the denominator) faster than NOPAT growth. ROCE held up better at 18.1%, reflecting that operating profitability per pound of capital employed is intact even as the acquired-goodwill drag hits ROIC.

---

Valuation — current vs its short history

The stock has derated meaningfully. P/E is below its six-year average (22.2x vs 25.3x); EV/EBITDA is 14% below its mean; P/Sales is 32% below its mean. The 2021 multiple peak (37x P/E, 22x EV/EBITDA) marked the top — investors paid for hyper-growth at the time of the AIM listing transition. Today, despite materially better cash generation and balance-sheet profile, multiples have compressed. The market is paying the lower of "growth premium" and "consultant multiple" — currently the latter.

---

Peer comparison — premium for growth, justified

Elixirr's premium to most peers is real but small once you account for growth. Its trailing P/E of 22.2x sits between Accenture (21.4x) and Huron (29.6x), and its EV/EBITDA at 11.5x is below every peer except ICF (which is shrinking). What Elixirr offers that none of these peers can match is 38% trailing revenue CAGR with margins still north of 19%. BAH's headline ROE of 90% is a leverage artefact — its equity is depressed by share buybacks. On underlying capital efficiency, Elixirr sits in the upper quartile.

ELIX is the high-growth outlier on the right. By the simple rule of paying a 1.0x EV/EBITDA point per percentage point of growth (rough industry heuristic), Elixirr at 11.5x EV/EBITDA on 38% growth screens cheapest in the group on PEG-style logic.

---

Fair value — three scenarios

The base case is broker consensus: $14.30, implying 45% upside from $9.85. The asymmetry favours the long: bear-case downside is roughly 19% to $7.95 if margin compression accelerates and the multiple rerates to a slow-growth-services 15-16x; bull-case upside is 71% to $16.82 if Hypothesis integrates cleanly and operating margin recovers above 22%.

---

Closing read

The numbers confirm that Elixirr is what its bull case claims: an asset-light, high-return, cash-generative consultancy growing several times faster than Accenture or FTI at comparable margins and lower multiples. They also contradict the "premium-priced AIM growth stock" narrative — on every multiple, Elixirr now trades at a discount to its own six-year history and sits in the middle of the peer pack despite owning the best growth profile in that pack. What you should watch next year is operating-margin direction in the H1-2026 print and goodwill commentary in the FY2026 audit; if margins re-cross 22% the stock rerates back to the historical 25x P/E and the consensus target is conservative, while a third consecutive year of margin slippage would force the market to treat the growth as bought rather than earned.

Figures converted from GBP at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

Where We Disagree With the Market

The sharpest disagreement: the market is pricing Elixirr as if it sits inside the same AI-substitution trade that has cost Accenture roughly 40% of its market value over the past year — and the evidence says the exposure runs the other way. ELIX's adjusted EBITDA margin expanded from 28.0% to 29.6% through FY25, the same period in which Accenture's margin compressed; it has no junior pyramid to cannibalise, has already deployed 45 internal AI agents, and grew AI-attributed revenue 260% YoY. The 32% P/Sales de-rate against the stock's own six-year mean (2.71x vs 3.97x) reads as sector pricing applied without business-model differentiation. We carry one supporting variant — that the 640bp statutory operating-margin compression from FY23 to FY25 is mostly mechanical acquired-intangible amortisation, not structural decay — and one institutional variant — that the persistent valuation discount is implementation friction ($2.3M five-day capacity), not earnings doubt. The combined view: the tape consensus is wrong about why the stock is cheap, and the H1 FY26 trading update (mid-July 2026) is the higher-information signal both advocates have under-weighted because the Stan verdict points everyone at the September print.

Variant Perception Scorecard

The 62 variant strength reflects three things: the AI-asymmetry disagreement is materially evidenced (Numbers, Business, Story tabs all stack the same way), but resolution gates on a single print four months out, and the sell-side already partially shares the bull setup — what is genuinely non-consensus is the price-action consensus that the discount should hold. Consensus clarity is high on the tape (17.8% drawdown from the September peak, fresh death cross 2026-03-05, P/Sales 32% below own mean) and bifurcated on the sell-side (19 buys, +53% upside cited but a $14.30 broker midpoint). Evidence strength is the most defensible leg — the upstream forensic, business and historical work converge.

Consensus Map

The map deliberately separates price-action consensus from sell-side consensus. Sell-side reads bullish (19 Buys, broker midpoint $14.30 = +45% upside); the tape reads cautious-to-negative (-17.8% from peak, fresh death cross). When those two diverge, the marginal-investor consensus is the price action — and that is what we are taking the other side of on issues 1 and 2.

The Disagreement Ledger

Disagreement 1 — AI as asymmetric upside. Consensus would say ELIX is a sub-scale consultant in a sector that AI is structurally compressing — every listed peer has de-rated and ELIX has come along for the ride. Our evidence disagrees on a specific, model-level point: ELIX has no graduate-analyst pyramid to defend, so AI cannibalises competitor revenue but absorbs the junior workload that ELIX never had. The FY25 datapoint that the market is over-discounting is direction-of-margin: 160bp of expansion at ELIX in the same year ACN's margin compressed and ACN's stock dropped 40%. If we are right, the market would have to concede that the consulting AI trade is bifurcated — pyramid firms compress, partner firms expand — and the 5y-mean P/Sales of 3.97x becomes the floor, not the ceiling. The cleanest disconfirming signal is the H1 FY26 adj. EBITDA margin: anything below 27% with AI revenue mix flat says the asymmetry is rhetoric.

Disagreement 2 — Margin compression is mechanical amortisation. Consensus says the statutory operating margin slide from 26.3% to 19.9% in two years is fundamental erosion. Our reading: capex is still 0.16% of revenue, D&A is overwhelmingly amortisation of acquired intangibles (Forensics B4: green flag, "asset-light consultancy, nothing to capitalise"), and the gap between adjusted EBITDA margin (held 28-30%) and statutory operating margin widened in lockstep with M&A cadence. If we are right, the market would have to concede that the right denominator for valuation is adjusted EBITDA less a normalised SBP charge ($6.3M FY25), not statutory operating income — and the multiple math changes by 200-300bp. Disconfirming signal: H1 FY26 statutory margin at 18% or below would force us to retire the "transient amortisation" framing and accept structural compression.

Disagreement 3 — Discount is liquidity, not earnings. Consensus reads the 32% P/Sales de-rate as a verdict on quality. Our reading: institutional ownership at 1.6% per TipRanks (vs ~28% insider) and a five-day capacity of $2.3M mean the marginal buyer pool is too thin to set a price at the analytical fair value. The 28 April 2026 secondary placing was explicitly structured "to broaden the institutional shareholder base" — an admission that liquidity is the binding constraint, not valuation. If we are right, the market is correct on fundamentals and we are still wrong on payoff — the discount persists until float expands. Disconfirming signal: a clean H1 FY26 print and tighter spreads, with no rerate — the institution-implementation thesis would survive only if liquidity remains the constraint.

Evidence That Changes the Odds

The two heaviest items are #1 (adj. EBITDA margin direction) and #3 (the gap composition). They are linked: if the gap is dominated by amortisation that fades, statutory margin should re-expand and the de-rate is unjustified; if the gap is driven by recurring SBP and judgment-based fair-value movements, the bear is correct and we are over-paying for adjusted earnings. Item #4 is the existential risk to the trade — being right on fundamentals while liquidity keeps the price unpaid.

How This Gets Resolved

The resolution path is asymmetric on time and information. Signals 1, 2 and 3 land inside a five-month window (mid-July trading update through September interim) and resolve disagreements 1 and 2 cleanly. Signal 6 — liquidity — is the slow signal that determines whether we get paid even if the analytics are right. A PM following one signal should follow signal 3 (mid-July trading update) because it pre-tells signals 1 and 2 by ten weeks and gives the most time to act.

What Would Make Us Wrong

The strongest counter is the bear's denominator argument. If FY26 organic growth comes in below 10% while the adj. EBITDA premium to operating income widens further, our reading collapses: the AI-asymmetry framing was a one-year mirage, the margin expansion was Hypothesis-mix specific, and the market was correct to apply the sector AI de-rate. The whole "no junior pyramid to cannibalise" argument becomes a story without a product when organic growth itself is the cyclical variable. We have one year of supportive data; the bear has two years of statutory compression and a widening add-back stack. A second consecutive year of margin compression and a narrowing AI-revenue contribution would force us to retire the variant and concede the bear's read.

The second counter is structural rather than tactical: ELIX has never been tested through a real consulting recession. It IPO'd into the post-COVID rebound, expanded through the rate-hiking cycle, and is now riding the AI wave. The senior-led model that recruits in good times can disperse in bad ones — partners with vested equity options and no client demand have outside options (start a boutique, take their book to McKinsey). If H1 FY26 prints alongside a broader consulting downturn — Accenture, Capgemini and the Big Four warning together — the asymmetric-tailwind variant would be testing precisely against the conditions that have never been seen. We do not have the data to underwrite that outcome.

The third counter is the implementation tax. Even if we are right on items 1 and 2, item 3 says the discount may not close until liquidity expands materially. FTSE 250 inclusion is mathematically out of reach in the June 2026 review (cap rank ~351 typically requires ~$1.3B). The first plausible inclusion window is January 2027, conditional on a material rerate that the variant itself is meant to drive. If we are right on fundamentals and the discount persists for two years because the marginal-buyer pool stays thin, the trade is correct and the carry is wrong.

The fourth counter is the founder-selling pattern. If the 28 April 2026 placing turns out to include Newton stock, the market will read that as a more reliable forward indicator than any of the upstream tabs we have leaned on. We are taking the side of the analytical case against the founder's revealed preference; we should be honest that "the man who built it is selling at depressed prices" is a hard signal to outweigh.

The first thing to watch is the H1 FY26 trading update on or around 14 July 2026 — specifically whether it includes any quantitative organic-growth colour or an "ahead of expectations" framing, and whether the AI revenue mix is named as a contributor.

Figures converted from GBP at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

Bull and Bear

Verdict: Watchlist — both advocates agree the H1 FY26 organic growth print in September 2026 is the single resolving event, and it is four months away.

The Bull case is real: ELIX is the only listed consultancy combining 30%+ adj. EBITDA margins with 30%+ revenue growth, sits on Accenture's multiple for nine times the growth, and runs a non-pyramid model that is genuinely a tailwind in an AI cycle that is hurting every listed peer. The Bear case has equally serious teeth on accounting quality: statutory operating margin has compressed 640bp in two years while the Adjusted EBITDA premium to operating income has widened from 12% to 49%, FCF-after-acquisitions was negative $4.6m in FY25, the company swung from net cash to $32.5m net debt on an $80.8m raise, and tangible book is negative $74.1m. Crucially, both sides name the same number as the test — H1 FY26 organic growth — which means there is no edge buying ahead of it; the watchlist verdict converts to Lean Long if organic prints ≥12% with adj. premium narrowing, and to Avoid if organic falls below 10% with the gap still widening.

Bull Case

Target and trigger. Bull's price target is $15.25 (12.5x Accenture's EV/EBITDA on FY26E adj. EBITDA of $66m, less $32.5m net debt, on ~50.5m shares), 12–18 month horizon. Primary catalyst: H1 FY26 interim (September 2026) showing organic growth ≥12% without a fresh acquisition wave, paired with adj. EBITDA margin holding 28%+. Disconfirming signal: H1 FY26 organic below 10% with adj. margin breaking 25%, or a goodwill impairment on the $232.7m carrying value — either forces exit.

Bear Case

Downside and trigger. Bear's downside target is $6.90 (-30% from $9.85), method 14× FY26 statutory diluted EPS of ~49¢ — a re-rate from the 22× currently paid on Adjusted EPS to the BAH/ICFI mid-teen multiple paid on statutory professional-services EPS, plus a small haircut for goodwill concentration. No impairment is required for the downside; the rerate alone delivers it. Primary trigger: H1 FY26 organic revenue growth printing below 10% without acquisition help. Cover signal: H1 FY26 statutory operating margin reclaims 22%+, FCF-after-acquisitions turns positive (>$20m), AND organic holds 12%+ — all three together kills the thesis.

The Real Debate

Verdict

Watchlist. The Bull case is the more interesting story — a genuine peer-group outlier on the growth/margin combo, a non-pyramid model that is structurally advantaged in an AI cycle, and a founder with $113m at risk owning 22.85% of the company — but Bear carries more weight on the question that matters near-term, which is whether the headline numbers describe the economics. Statutory operating margin has compressed 640bp, FCF-after-acquisitions was negative in FY25, and the company funded its own buyback with $80.8m of new debt; those are facts, not interpretations. The single most important tension is the quality of H1 FY26 organic growth: both Bull and Bear name the same September 2026 print as the resolving event, which means there is genuinely no edge in committing capital before it lands. Bear could still be wrong if H1 FY26 prints ≥12% organic with the adj. premium narrowing, in which case the multiple re-rates and the discount closes — but the reverse scenario is equally available and the balance sheet has just lost its cushion. The condition that flips this verdict is the H1 FY26 interim itself: organic ≥12% without acquisition help and adj. EBITDA premium to operating income narrowing toward FY24 levels moves it to Lean Long; organic below 10% with the gap still widening moves it to Avoid.

Catalysts — What Can Move the Stock

Figures converted from GBP at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

The next six months hinge almost entirely on one print: the H1 FY26 interim results around 22 September 2026, with a meaningful tell from the mid-July trading update beforehand. That sequence is where the market finds out whether organic growth holds 12%+ now that Hypothesis is fully wrapped and TRC is in the comp — the single number that resolves the "growth bought vs earned" debate keeping the EV/EBITDA at a non-existent premium to Accenture. The AGM (late June) carries unusual weight as the first remuneration vote under the Main Market regime, with three explicit UKCG opt-outs on the ballot. Outside those, the calendar is medium-thin: the $15.9m secondary placing closed two days ago is now in the rear-view; the death cross on 2026-03-05 is reassertion-of-trend territory; and FTSE 250 inclusion — repeatedly cited by management as the medium-term anchor — is mathematically out of reach in any 2026 review at the current ~$497m cap.

Ranked Catalyst Timeline

Date windows beyond 22 September 2026 are estimated from prior-year cadence (H1 25 trading update was 14 Jul 2025; H1 25 interim results 22 Sep 2025; FY24 AGM 24 Jun 2025). The company has not published a formal 2026 financial calendar to RNS.

Impact Matrix — Which Catalysts Resolve the Debate

The matrix is unusually concentrated: of six items, only two — the September interim and the AGM — actually resolve the underwriting debate cleanly. The other four either pre-tell September (the July update) or add side-information that reinforces a thesis already in motion (TRC true-up, insider dealing, next deal). A PM who can only follow one event should follow the September print.

Next 90 Days

The next 90 days run to ~30 July 2026. Four items inside that window:

• ~25 May 2026 — Paper Annual Report distribution. Substance is already on the FCA NSM; this is a low-impact administrative date but worth scanning for any RemCo policy changes (clawback adoption would upgrade governance grade) and confirmation of the FY25 contingent consideration true-up methodology. PM matter: only if disclosures contradict the digital AR.
• ~24 June 2026 — AGM. First remuneration vote under the Main Market regime. ISS/Glass Lewis recommendations typically publish 2-3 weeks before the meeting — that is the actionable read. AGM-day RNS often includes a short trading statement; that statement, not the votes, is the price-mover. PM matter: a protest vote >=20% on remuneration is a structural cap on multiple expansion; "in line with expectations" trading colour is mildly positive.
• ~26 June 2026 — FTSE UK Index June review effective. ELIX is well below the FTSE 250 threshold and will not be promoted; this matters only because management has made FTSE 250 inclusion a stated medium-term ambition. The June review is the first opportunity for the market to mark the timeline as "later than implied." PM matter: low — unless mgmt repeats the ambition with new specificity at AGM.
• ~14 July 2026 — H1 FY26 trading update. This is the main 90-day event. Watch the language vs the 14 Jul 2025 update ("continued growth, maintaining track record of profitable growth") and any quantitative colour on organic vs inorganic split. PM matter: the highest-information signal in the next 90 days because it pre-tells the September interim that resolves the central debate.

The September interim falls just outside the 90-day window (day 144). The 90-day calendar is therefore positioning-only; the underwriting decision is made in late September.

What Would Change the View

The investment debate over the next six months will be settled by three observable signals, in this order. First, the H1 FY26 organic growth print on or around 22 September 2026 — anything below 10% confirms the bear's roll-up critique and forces a multiple reset to statutory P/E; anything at 12% or above with margin holding 28%+ vindicates the bull case and rerates the stock toward broker consensus $14.30. Second, the trajectory of FCF after acquisitions and net debt — a positive H1 FCF-after-acquisitions number with net debt below $39.7m would retire the "self-funded compounder is dead" narrative the bear leans on; a deteriorating reading widens the gap between adjusted and statutory metrics that the market is currently ignoring. Third, founder insider direction — Newton stepping up open-market buying (versus continued slow selling) at any price would be the single highest-conviction insider signal in the file and would close the governance discount. None of the other items on the calendar — AGM, FTSE review, paper AR, next bolt-on — change the underwriting independent of these three. The thesis-changers are concentrated, well-dated, and observable; the calendar is otherwise medium-thin.

Figures converted from GBP at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

The Full Story

The story management told the market changed twice. From the 2020 AIM IPO through FY2022, Elixirr was a "challenger consultancy" using a four-pillar growth model, racking up COVID-era revenue records and acquiring a digital, procurement and data platform. Through FY2023–FY2024, the narrative quietly mutated: organic growth decelerated, margin tailwinds reversed, the "outperforming the consulting market" language disappeared, and the move to the LSE Main Market was repurposed as cover for withdrawing explicit revenue and margin guidance. FY2025 reset the story around AI: 260% AI-revenue growth, an "AI-native" non-pyramid model, and an explicit FTSE 250 ambition. Credibility on headline revenue is strong; credibility on what gets quietly dropped from the script is mixed.

1. The Narrative Arc

The confidence dip in FY2024 is real and it shows up in three places at once: organic growth language goes from "accelerating" to passive-voice math, the FY2023 line about "outperforming the global Consulting market" is never repeated, and explicit forward revenue and margin guidance is withdrawn for the first time since IPO. FY2025 reset the tone — but on a different basis (AI, FTSE 250) than the original IPO promise (organic challenger growth).

2. What Management Emphasized — and Then Stopped Emphasizing

Each cell scores how prominently a theme featured in that year's annual report and CEO letter (0 = absent, 10 = front-and-centre). Watch the verticals: "Outperforming the market," "ESG/sustainability," and "House of Brands / venture arm" all peaked, then went quiet. AI, Rule of 50, FTSE 250, and "AI-native" arrived late and dominated FY2025.

Three patterns matter:

1. The $1.35bn-by-2028 unicorn ambition (introduced FY2022, peaked FY2023) was quietly retired. By FY2025 it's gone — replaced with "FTSE 250 inclusion" as the medium-term anchor. Both targets imply ~$1.35bn EV, but FTSE 250 is a softer, more defensible commitment with no calendar deadline.
2. "Outperforming the global Consulting market" went from peak claim in the FY2023 CEO letter to absent in FY2024. This was the year Accenture, Capgemini and the Big Four all warned on consulting demand. Management chose silence over reconciliation.
3. AI went from a sub-theme (iOLAP framing, FY2022) to the organising principle (FY2025). The FY2025 report explicitly recasts the firm's non-pyramid model as "intentionally built to harness the technologies of tomorrow" — a retroactive narrative.

3. Risk Evolution

The risk register has gotten more granular but less alarming. New entries (AI delivery quality, cyber, talent inflation in tech roles) replaced older ones (COVID, Russia/Ukraine boilerplate). Climate-related risk is acknowledged but explicitly not classified as principal — a notable choice given the Main Market upgrade.

Two things to flag:

• FX risk has been quietly upgraded as the US share of revenue went from ~10% at IPO to 63% in FY2025, but it's still not classified as principal. With $107.7m of US-denominated debt now drawn and a Chicago-anchored TRC, GBP/USD sensitivity is now real and material.
• M&A integration risk has stayed high (8–9) while the company keeps acquiring at faster cadence. TRC and Kvadrant land in the same six-month window — the largest two deals in the firm's history, on top of Hypothesis still bedding in. Management language is reassuring; the risk profile is not.

4. How They Handled Bad News

Elixirr has not had a "scandal." It has had four moments where the numbers stopped supporting the script. How management talked through each is the most honest read on credibility.

5. Guidance Track Record

Five years of explicit forward guidance, then withdrawal in FY2024. The headline revenue and margin numbers landed inside or above the bands every year. The deltas reveal where management is calibrated and where they sand-bag.

The track record on revenue is straightforwardly good — four years, four landings inside or above the band. The pattern is conservative anchoring at guidance issuance (lower band always credible) followed by upper-band or above-range delivery. That's a reasonable management-speak signature: under-promise on the headline, deliver the headline, let the market do the upgrade.

The margin track record is weaker. Each year's guided range stepped down from the prior achieved level (29% guided after 31% achieved; 28% midpoint after 30% achieved; 28% after 29.6%). Management consistently signalled margin compression and consistently delivered roughly at the guided floor — fine, but unmistakably a downward drift the headlines didn't flag.

7/10. Strong on revenue delivery, honest on the margin direction even when not loudly. Two real demerits: the FY2024 guidance withdrawal under regulatory cover, and the disappearance of inconvenient claims (the $1.35bn-by-2028 unicorn target; "outperforming the global Consulting market") rather than explicit retraction. The FY2025 candour on the AI-bear thesis pulls the score back up. This is competent IR with editorial instincts, not a clean-glass operator and not a serial spinner.

6. What the Story Is Now

The current story, stripped to its frame: Elixirr is an AI-native, US-anchored, equity-aligned challenger consultancy with a credible Main Market presence, a working cross-sell flywheel, and a disciplined-but-aggressive M&A engine. The growth model is more durable than the FY2024 wobble suggested; it is also more dependent on continued M&A success and AI-led deal expansion than at any prior point.

What to believe: the AI revenue acceleration is real and quantified; cross-sell is mechanically delivering; partner productivity ($5.9m revenue per partner, up from $5.1m) is genuinely improving; the US-anchored operating model is now scaled, not aspirational.

What to discount: assertions of structural margin durability above 29% (six-year track record drifts down); claims that recent acquisitions are the "right kind" of deal (TRC and Kvadrant haven't been through a full integration cycle yet); the implicit framing that the FY2024 guidance withdrawal was housekeeping rather than caution.

What to watch: whether organic growth holds 15%+ in FY2026 without acquisition help, whether the AI-revenue mix re-accelerates or plateaus near 8–10%, and whether the FTSE 250 ambition becomes a calendared target with accountability or stays open-ended.

Figures converted from GBP at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

The Forensic Verdict

Elixirr's headline numbers are not fabricated, but they are heavily polished. Operating cash flow is real, capex is genuinely trivial, the auditor (Crowe U.K. LLP) has issued a clean opinion, and there is no restatement, regulatory action, or short-seller report on file. What raises risk is the gap between what management foregrounds — Adjusted EBITDA, free cash flow, organic growth — and what the statutory P&L and balance sheet show: net-income margins compressing from 20% to 13% in two years, free cash flow fully consumed by acquisitions in 4 of the last 5 years, intangibles now 79% of total assets, a $56.8M contingent-consideration liability sitting on a 77% probability-of-maximum assumption, and a Main Market debut paired with a swing from $9.4M net cash to $38.2M net debt. None of those facts is hidden — but each pulls in the opposite direction from the "industry-leading profitability, strong cash generation" framing. The single data point that would most change the grade is whether organic growth holds up next year without a fresh acquisition; if it does, several yellow flags collapse. Forensic Risk Score: 48 / 100 — Elevated.

Shenanigans scorecard — all 13 categories

The two genuinely red items — M&A-distorted cash flow and a widening non-GAAP gap — are linked. As acquisition cadence has accelerated, both the items management is allowed to add back (acquired intangible amortisation, contingent-consideration movements, deal costs) and the items it chooses to add back (share-based payments) have grown disproportionately. The result is an Adjusted EBITDA that beats the statutory operating line by half, and a free-cash-flow figure that disappears once the cash spent on acquiring the businesses generating that EBITDA is subtracted.

Breeding Ground

The governance setup amplifies the accounting risk rather than dampening it. Stephen Newton, the founder CEO, owns 22.85% of the shares and approved the FY25 directors' report; his and co-founder Graham Busby's combined $3.75M FY25 variable remuneration is roughly four times their combined base salary, and the underlying performance targets are explicitly withheld as commercially sensitive. The Remuneration Committee did not engage an external consultant in FY25, and the company is openly non-compliant with three UK Corporate Governance Code provisions covering vesting periods, malus and clawback. Crowe U.K. LLP has audited Elixirr for seven years; that is sub-tenure-rotation but worth tracking after the recent move from AIM to the Main Market, which raises the company's regulatory and reporting bar.

The breeding-ground score is yellow, not red, because the founder is on the same side of the equity stack as ordinary shareholders (11.4M-share direct holding, eight-figure economic interest). But the lack of malus/clawback means there is no formal mechanism to recoup variable pay if a future restatement materialises, and the discretionary nature of bonus targets weakens the link between disclosed performance metrics and disclosed remuneration. Three UK Code non-compliances stacked on a first-year Main Market filer is the kind of profile that institutional governance teams will keep flagging until the regime tightens.

Earnings Quality

Earnings exist, but their quality is deteriorating in two ways the headline metric hides. First, the gap between the Adjusted EBITDA management points to and the statutory operating profit has widened from 12% (FY23) to 49% (FY25). Second, statutory net-income margin has compressed from 20% to 13% over the same window, even as Adjusted EBITDA margin has held at 28-30%. Both moves are driven by the same underlying mechanic: acquired-intangible amortisation, share-based payments, and contingent-consideration movements are growing faster than revenue, and they are being routinely excluded from the headline.

Adjusted vs statutory profitability — the gap is widening

The Adjusted EBITDA margin line is flat at 28-30% — the picture management presents. The statutory operating margin has fallen 640bp in two years (26.3% → 19.9%), and the statutory net margin has fallen 690bp (20.1% → 13.2%). The drivers are visible in note 3 of the FY25 accounts: amortisation of acquired intangibles, share-based payment charges ($6.3M, +90% YoY), Main Market listing costs, acquisition-related professional fees, and movements in contingent-consideration fair value. Calling these "adjusting items" in a serial acquirer where the next deal is already announced (Kvadrant, January 2026) is a definitional choice, not a statement of fact.

Adjusted Diluted EPS premium has tripled

The 58% premium of Adjusted EPS over statutory EPS in FY25 is large by professional-services-rollup standards. Investors anchoring on the $0.79 Adjusted Diluted EPS figure are anchoring on a number that bears progressively less relation to the $0.50 reported under IFRS.

Receivables vs revenue — DSO has drifted, even after FY25 strong-collections base

DSO has migrated from 50 days in FY20 to 67 days in FY25. The FY24 step-down to 62 days was a clean collections result that management explicitly acknowledged would reverse, which it did. The auditor (Crowe) flagged revenue recognition as a Key Audit Matter in FY25, with specific concern about Group components that "did not operate a timesheet system" — meaning some entities recognise services revenue based on management estimates of effort rather than measured time. That is normal in consulting after acquisitions but it is a judgmental area worth noting alongside the DSO drift.

Cash Flow Quality

Operating cash flow is genuine — the company collects cash from its services, working capital is normal for consulting, and capex is essentially zero. The forensic problem is that management's "strong cash generation" framing materially overstates how much cash is left for shareholders once the cash needed to acquire the next year's growth has been spent.

Three lines tell the story: CFO, FCF, and FCF after acquisitions

In FY22, FY23, FY24 and FY25, acquisitions consumed 116%, 90%, 72% and 110% of operating cash flow respectively. FCF after acquisitions has been negative twice (FY22, FY25) and below $13M four times in the last five years. The 11% FCF growth management celebrates in FY25 ($35.2M → $41.9M, the company-defined FCF includes lease repayments) sits next to a FCF-after-acquisitions of negative $4.6M and an $80.8M debt issuance to fund the TRC purchase and earn-outs. The economic free cash flow for shareholders, after replenishing the inorganic engine that drives 13-15 percentage points of the headline 34% revenue growth, is materially lower than the figure reported.

Working-capital contribution and the FY24 collections reset

FY24 was the year working-capital and non-cash items contributed $8.1M of CFO above pre-tax profit, driven by the December 2024 collections push management has now disclosed. FY23 was the inverse — CFO ran $6.7M below pre-tax profit because of receivables build. This volatility means single-year CFO/NI ratios are misleading. The 3-year averaged CFO/NI is 1.66, which is healthy for a consultancy, but it understates the cyclicality: the band runs from 0.97 (FY23) to 1.79 (FY24).

Net cash to net debt — the FY25 inflection

Cash has fallen every year since FY21, despite Adjusted EBITDA quadrupling. $80.8M of new debt was issued in FY25; of that, $39.3M funded TRC, $18.4M went to EBT share buybacks (offsetting employee dilution), and $9.7M went to earn-out and holdback payments on prior deals. The remainder rolls forward to fund FY26 commitments including Kvadrant ($24.2M maximum consideration) and the residual TRC contingent consideration ($56.8M on the balance sheet at year-end on a 77%-of-max probability assumption). The company is moving from a self-funded growth model to a debt-funded one, which is a different risk profile than the "strong cash generation" framing suggests.

Metric Hygiene

Management's KPI panel is consistent year-on-year, but it is also constructed in a way that systematically drops the metrics where the company is doing worst. Net debt does not appear in the FY25 highlights panel; statutory EPS does not; goodwill-to-equity does not; FCF-after-acquisitions does not. What appears is Adjusted EBITDA, Adjusted EBITDA margin, Adjusted Profit Before Tax, Adjusted Diluted EPS, dividend per share, free cash flow (defined inclusively of lease payments), and revenue. The metrics dropped from headline disclosure are exactly the metrics that have moved adversely. This is the textbook "showcasing misleading metrics" pattern — not because any individual disclosure is wrong, but because the curated set is asymmetric.

The two metrics most worth recalibrating before underwriting: (1) statutory EPS is now $0.50, not $0.79, and the gap is widening; (2) free cash flow available to shareholders, after the M&A engine, is single-digit millions, not $41.9M. The other metrics are honest if you read the small print, but a reader who looks only at the highlights panel will form a materially different view than one who reads the cash-flow statement and note 3.

Soft assets are now most of the balance sheet

Of the $265.7M intangibles balance, $232.7M is goodwill — a single line item the auditor flagged as a Key Audit Matter, with management's impairment model resting on long-term growth and discount-rate assumptions. With statutory operating income at $40.0M, a single goodwill impairment event of even 10% would wipe a year's reported operating profit. The risk is not that an impairment is imminent — there is no audit signal it is — but that the carrying value of goodwill has grown faster than the underlying earnings power, narrowing the cushion.

What to Underwrite Next

The forensic risk here is not a thesis-breaker. It is a valuation and position-sizing question — specifically, whether to value the business on its statutory P&L (where margins are compressing and EPS growth is decelerating) or on its Adjusted EBITDA (where margins are stable and growth is intact). The honest answer for FY26 underwriting is somewhere in between, with explicit dollar adjustments rather than a blanket trust in either number.

A signal that would upgrade the grade: the FY26 results show statutory operating margin recovering toward 24%+, Adjusted EBITDA premium narrowing, FCF after acquisitions positive in both halves, and DSO normalising below 60 days. A signal that would downgrade the grade: any auditor change, a restatement of contingent-consideration accounting, statutory net income flat or down on rising revenue, or a goodwill impairment.

The accounting risk at Elixirr is real, recurring, and well-disclosed once you go past the highlights panel. It is not a fraud signal. It is a serial-acquirer signal: M&A drives the headline numbers, the headline numbers are then adjusted up to hide the dilution and amortisation cost of that M&A, and the cycle repeats. Investors who model the company on FCF-after-acquisitions and statutory EPS will arrive at a defensible valuation; investors who model it on Adjusted EBITDA and management-defined free cash flow will pay a premium they may not realise they are paying.

The People Running Elixirr

Figures converted from GBP at historical FX rates — see data/company.json.fx_rates. Ratios, margins, multiples, share counts and percentages are unitless and unchanged.

Governance grade: B+. A founder-led consultancy with genuine skin in the game — CEO Stephen Newton owns 22.85% (~$113m at 744p / FX 1.3242) and the wider insider/director group ~28% — yet the governance scaffolding around the equity is thin. The 2025 Main Market admission has tightened disclosure, but the company explicitly opts out of three UK Corporate Governance Code provisions (no malus/clawback, sub-five-year RSA vesting, no director shareholding policy), and a March 2026 employee option reprice and a string of insider sales by the founder leave the alignment story imperfect rather than airtight.

1. The People Running This Company

The leadership has real consulting pedigree: Newton and Busby co-founded Elixirr in 2009 after senior partner roles at Accenture, and the Chairman is a credible heavyweight (BT, Salesforce). The new CFO Willott and new Deputy CEO Busby both took up enlarged roles on the same day — 1 January 2025 — which means the financial control function changed hands in the same year as the Main Market admission and a busy M&A programme. That is a thin succession bench: the entire executive layer is two co-founders plus a recent CFO promotion.

2. What They Get Paid

The pay mix is dominated by the cash annual bonus: Newton's $1.88m bonus was 4× his $469k base, taking total comp to $2.46m. On $26.5m of FY25 net income, the three executive directors drew roughly 22% of net profit in pay — high in absolute terms for a ~$487m-cap company but defensible because Newton's true wealth lever is his ~$113m equity stake, not the pay packet. The salary line itself is modest for a CEO running a $200m-revenue listed firm.

3. Are They Aligned?

Ownership & control

CEO Stephen Newton's 22.85% is the controlling individual stake. Including co-founder Busby (3.49%), other directors (~2.2%), and substantial individual shareholder Ian Ferguson (4.47%), insiders/related individuals control ~33% — enough to set strategic direction and to defend or block any control transaction. Institutions (Gresham House, Slater, Rathbone, Grandeur Peak, Otus, JPM, abrdn) own a similar share of the register, with no single hostile block.

Insider buying vs selling

The recent disclosed transactions are mixed but small in scale: NED Charlotte Stranner sold ~$501k worth (Jan 2024); Simon Retter (Rem-Co Chair) made small open-market purchases of ~$13k (Feb 2026) and ~$14k (Mar 2026). Founder Stephen Newton's headline holding has drifted lower over five years (~25–29% pre-IPO/AIM era → 22.85% as of March 2026), reflecting periodic founder placings. He has not been a buyer at any point since IPO. Stockholders should treat the founder as a slow seller.

Dilution and option repricing

Capital allocation

Capital deployment in FY25 was disciplined-but-busy: the TRC Advisory acquisition; a 27% YoY increase in dividends to ~30¢ per share (~$11.3m total); ~$32.5m year-end net debt against ~$68.7m of facility headroom. Post year-end: Kvadrant acquisition (Jan 2026, ~$24m, partly stock-funded). Dividends grew faster than net income in FY25, but the Board funded that out of cash from operations rather than leverage. Operating cash flow comfortably covered the $11.3m payout. Acquisitions are the dominant use of cash, consistent with the partner-led roll-up model.

Skin-in-the-game scorecard

Factor	Reading
Founder/CEO stake	22.85% (~$113m) — strong
Wider insider holding	~28% — strong
NED shareholdings	Modest but real ($1.7m – $2.7m each)
Founder activity	Net seller over 5 years — drag
Formal shareholding policy	None — drag
Clawback/malus	None — drag
RSA vesting	3 years (below UKCG 5y) — drag

A 7/10. The economic alignment is genuine and large; the policy scaffolding around it is below FTSE 250 norms.

4. Board Quality

The Audit and Remuneration committees are chaired by genuine financial professionals (Stranner and Retter, both qualified CAs with AIM/small-cap experience). The Chair (Patterson) is the anchor of independence and brings real big-cap and digital experience, which Newton — who has never run a public company before — would otherwise lack. The addition of Bill Michael at the end of January 2026 deepens the professional-services and Big-4 bench, which is genuinely useful for a consultancy preparing M&A integration and accounting judgements (goodwill: ~$233m at year-end is the single largest balance-sheet item).

The structural weakness is scale and tenure: 6 directors at year-end (now 7), with 5 of them appointed at or around the 2020 AIM IPO. They have served together long enough to be cohesive, but no NED rotation has happened in five years and the Stranner/Retter pair are simultaneously committee-chairs and audit-committee/remuneration-committee members. The Code's "must consider tenure" pressure builds from year seven; that clock is ticking from mid-2027.

5. The Verdict

Strongest positives. A founder who still owns 22.85% of the company (~$113m) writes a powerful incentive contract that no policy document can replicate. The Chairman is genuinely heavyweight, the audit and rem committees are CA-qualified independents, the auditor is clean, the balance sheet is conservative, and the dividend record is consistent with disciplined cash generation. There is no related-party self-dealing, no promoter pledging, no controversial director loans, no auditor disagreements.

Real concerns. Three explicit UKCG opt-outs (no clawback, sub-five-year RSA vesting, no shareholding policy); performance targets undisclosed; the founder is a quiet net seller and shows no track record of open-market buying; March 2026 employee option repricing transferred ~$13–19m of theoretical value from shareholders to staff (excluding directors); thin succession bench under the founder/co-founder pair; and one new NED carries reputational baggage from his KPMG exit.

The one thing that would move the grade.

• Upgrade to A− if the FY26 annual report introduces malus/clawback, formal director shareholding requirements (e.g., 200% salary), and discloses retrospective bonus targets. Plus a clean year of director open-market buying (not just selling) at current prices.
• Downgrade to B− if Newton continues to sell into strength while the company keeps repricing or re-issuing employee options, or if the goodwill on the balance sheet (~$233m, ~78% of total assets) takes a material impairment in FY26 alongside an earnings miss.

Web Research — What the Internet Knows

Figures converted from GBP at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

The Bottom Line from the Web

Two days before this research was pulled, Elixirr launched a $15.9m secondary share placing "to meet heightened institutional demand" — a placing that comes immediately after the FY2025 annual report and against a stock that has slid 17.8% from its September 2025 high of $12.18 (905.6p). The web reveals a company that is simultaneously executing (revenue $201.5m beat the $200.6m forecast, EPS beat consensus, ninth bolt-on acquisition closed, graduated from AIM to the LSE Main Market in July 2025) and pricing risk (analyst consensus target of $15.10 sits roughly 53% above spot, while the founder/CEO has been a steady seller and EV/EBITDA at 13× sits comfortably above the 6–10× boutique-consulting norm). The placing is the headline event the filings can't tell you about — it changes the float, dilutes existing holders, and signals that the company is taking the cash institutions are offering rather than waiting for a higher price.

What Matters Most

1. $15.9m secondary share placing launched ~29 April 2026 to broaden institutional base

2. FY2025 results beat — revenue $201.5m, EPS beat, dividend on track

Elixirr reported FY2025 revenue of $201.5m vs $200.6m consensus (+34% YoY from $139.5m), with EPS also exceeding expectations. The 2025 Annual Report was published on the FCA National Storage Mechanism on ~29-Apr-2026, with paper copies due ~25-May-2026. Q3 2025 (interim) had already pre-printed the trajectory: 0.29p EPS vs 0.22p consensus — a ~32% beat. (Sources: Investing.com transcript, 24-Apr-2026; MarketScreener; TipRanks; Investegate.) The market's tepid reaction (still 17.8% off the September peak) suggests the beat was already priced in and forward guidance is what is being discounted.

3. Stock drawdown of ~17.8% from $12.18 peak (Sep 30, 2025) — divergence from fundamentals

4. TRC Advisory acquisition (Sep 22, 2025) — largest ever, 9th total, 5th in the US

Elixirr announced the acquisition of TRC Advisory, LLC on 22-Sep-2025 — its largest deal to date, seventh since the 2020 AIM IPO, first since joining the LSE Main Market in July 2025, and fifth US acquisition. The deal was described as immediately earnings-enhancing. The cumulative roll-up now totals nine boutiques: Den Creative, Coast Digital, The Retearn Group, iOLAP ($40m, Mar-2022), Responsum, Insigniam, Hypothesis (Oct-2024), TRC Advisory (Sep-2025) and Kvadrant Consulting. (Sources: BusinessWire; Stockopedia/RNS; Investegate.) M&A is therefore the dominant capital-allocation activity — and explains the credit facility expansion and the share placing.

5. Credit facility expanded to $87.4m (Sep 2025) explicitly to fund more M&A and limit dilution

Elixirr expanded its revolving credit facility to $87.4m in September 2025 with the stated purpose of "supporting M&A growth strategy, limiting dilution." (Source: TipRanks, 18-Sep-2025.) Read against the $15.9m placing seven months later, the "limit dilution" framing has clearly bent — the company is using both debt and equity to keep the deal cadence going.

6. Promotion to the LSE Main Market in July 2025 — uplisting from AIM

Elixirr moved from AIM to the LSE Main Market in July 2025. This is the single biggest structural event of the past 12 months: it widens the eligible institutional buyer pool (many UK funds cannot hold AIM stocks), increases regulatory burden, and subjects the firm to UK Corporate Governance Code rather than the lighter QCA Code. The web framing across multiple sources is consistently positive ("expanding global challenger consultancy model"). (Sources: TipRanks, Investegate, BusinessWire 22-Sep-2025.)

7. Analyst consensus is constructive — target $15.10 vs $9.85 spot (~53% upside)

8. Insider buy by Simon Retter (Feb 24, 2026) — but founder has been a net seller

A small but recent positive: insider Simon Retter purchased 1,476 shares at $9.12 (677p) on 24-Feb-2026 (~$13.5k commitment). (Source: The Cerbat Gem.) Set against this, Simply Wall St (19-Jan-2025) flagged that Founder/CEO Stephen Newton has been selling, and TipRanks shows aggregate 3-month insider buying of only ~$3.4k. Founder ownership has stepped down across the disclosed snapshots: 29% (Oct-2022) → 25% (Jan-2025) → 24% (Dec-2025) — directionally consistent with founder profit-taking, even though absolute insider control remains very high (~42%).

9. CFO promoted to Deputy CEO; new CFO appointed (Dec 2024 / early 2025)

Co-founder Graham Busby was promoted from CFO to Deputy CEO in early 2025, with a replacement CFO named in the December 2024 announcement. (Sources: MarketScreener, 10-Dec-2024; Board of Directors page, 30-Jan-2026.) Busby has personally led the eight-acquisition build, so the elevation tightens M&A control at the executive level — and signals that the inorganic strategy is the next leg, not a one-off.

10. Margin compression in FY2024 (which the FY2025 results need to have reversed)

11. Clean reputational record — no SEC, Reuters or CNBC controversy hits

Repeated specialist queries for "scandal", "controversy", "investigation" and "SEC" returned no substantive matches across Reuters, CNBC and broader press. The Reuters company page exists with metadata only; CNBC explicitly states "There is no recent news for this security." Yahoo Finance shows ISS Governance QualityScore as N/A — no negative governance flag, but also no positive third-party assurance. (Sources: Reuters; CNBC; Yahoo Finance.)

12. Industry tailwind is real but Elixirr is a 0.04% slice of a $374B market

The global management consulting services market is $374.67bn in 2026, growing at a 4.7% CAGR to $471bn by 2031 (Mordor Intelligence). North America held 37.45% of the market in 2025. Tier-1 and tier-2 firms (McKinsey, BCG, Bain, Deloitte, KPMG, Accenture) account for ~60% of share. The 2026 trend narrative is dominated by AI/ML embedded in consulting offerings — Elixirr's pitch is consistent with this and its acquisitions (iOLAP, Hypothesis, TRC) align to data, insights and transformation. (Sources: Mordor Intelligence; Six Paths Consulting; IBISWorld.) The runway is huge, but the specific share gains require continued execution against giants.

Recent News Timeline

What the Specialists Asked

Insider Spotlight

Stephen Newton — Co-founder & CEO. Largest individual shareholder at ~24% (down from 29% at Oct-2022, 25% at Jan-2025). Has been a steady net seller across the disclosed snapshots. Founded the firm in 2009 after frustration with traditional consulting's "stagnated approach to innovation."

Graham Busby — Co-founder & Deputy CEO (former CFO). Promoted to Deputy CEO in early 2025. Personally owns the inorganic-growth agenda, having overseen all eight (now nine) acquisitions to date. The promotion structurally elevates the M&A engine.

Gavin Patterson — Chairman (since 2019). Former CEO of BT Group 2013–2018, where he led the UK superfast and ultrafast fibre rollouts. High-profile Chair brings governance credibility and likely opens doors at the FTSE-listed client tier.

Simon Retter — insider (purchased 1,476 shares at $9.12 on 24-Feb-2026 ~ $13.5k). The only confirmed insider buy on record in the past several months — small in dollar terms but the only positive directional signal from the insider class.

Charlotte (NED, July 2020). Independent Non-Executive Director, prior consulting relationship from April 2020.

Industry Context

The global management consulting services market is $374.7B in 2026, projected to grow at 4.7% CAGR to $471.4B by 2031 (Mordor Intelligence). The US market is $111.4B in 2025, growing 4.11% CAGR to $160.1B by 2034 (Globe Newswire / market research). North America is 37.45% of global share. The dominant 2026 narrative across multiple industry trackers is AI/ML embedded in consulting offerings — Six Paths Consulting's "Top Trends for 2026" lead with AI, scenario modeling, and data-driven advisory. Elixirr's nine-acquisition stack (especially iOLAP, Hypothesis and TRC Advisory) maps directly onto this trend.

Competitive structure: Tier-1/tier-2 firms (McKinsey, BCG, Bain, Deloitte, KPMG, PwC, Accenture, A.T. Kearney, Oliver Wyman) account for ~60% of the market (Grand View Research). The top-10 firms account for 47% of total consulting engagements (Business Research Insights). Mid-sized players grew their share by 18% in the most recent comparable period — the structural positive for ELIX is that the mid-tier is gaining share against the big-eight, not losing it.

Boutique valuation norms: Established consulting firms trade at 6–10× EBITDA (Intelek), with top-tier specialist boutiques commanding premium multiples. Midsize financial-consulting boutiques saw EBITDA multiples of 13–15× across 2020–2025 (First Page Sage), with ~14% growth in valuation over that period. ELIX's 13× EV/EBITDA sits squarely inside the boutique-premium band.

Liquidity & Technicals

Figures converted from GBP at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

Trading capacity is the binding constraint on Elixirr — average daily turnover of roughly $2.3M leaves the name on a watchlist for funds above ~$45M AUM at a 5% weight. Beneath that, the tape is mid-cycle: a 24% one-month bounce has lifted price back above the 50-day average but sits 2% below the 200-day, with a fresh death cross on 2026-03-05 still framing the trend.

Portfolio Implementation Verdict

Price Snapshot

Critical Chart — Full History with 50d / 200d SMA

Price is below the 200-day SMA ($9.85 vs $10.10, a 2.4% gap) after a death cross fired on 2026-03-05. The five-and-a-half-year arc shows three regimes: a 2020–2022 advance from sub-$3 to roughly $10, a 2022–2024 sideways grind around the $5.50–$7.50 band, and a renewed leg up through late-2025 that printed an all-time high near $11.86 before the most recent rollover.

Relative Strength

The configured broad-market benchmark for UK names is EWU, but no benchmark series was populated for this run, so a direct relative-strength chart is not produced. On absolute terms, ELIX is +52% over three years and +37% over five, comfortably above what a passive UK equity sleeve would have returned over the same window — but that strength was earned in the 2024 leg-up; the trailing twelve months are essentially flat (-2.1%) and YTD is -11.4%.

Momentum — RSI(14) and MACD Histogram

RSI(14) finished April at 61.8 — neutral-positive territory after touching a deeply oversold 24.8 in mid-March, the lowest reading of the trailing eighteen months. MACD has flipped positive again over the last three weeks, mirroring the price bounce off $7.79 on 2026-03-26. Near-term momentum is the most constructive piece of the puzzle — but the swings have been violent: RSI has now traversed from 79 (Sept-Oct overbought) to 25 (March oversold) and back into the high 60s in just six months, which argues for sized-down entries rather than a single block.

Volume, Volatility, and Sponsorship

Realised vol sits at 43% annualised — between the ten-year p50 (33%) and p80 (46%) bands. Volatility regime is best described as elevated-but-not-stressed: clearly above the 2023–2024 calm phase and approaching the post-2022 sell-off range, but not yet at the 65–80% peaks seen in March-April 2025. The biggest volume day of the past year (2026-04-29 at over 20× the 50-day average) printed flat — a transfer of inventory rather than a directional flush, which is consistent with the late-stage bounce reading.

Institutional Liquidity

Read this section before sizing anything. ELIX is flagged illiquid at the manifest level: average daily traded value of approximately $2.3M leaves only specialist long-only mandates and small-cap funds with the runway to enter and exit cleanly.

A. ADV and Turnover

ADV at 0.44% of market cap is light — institutional rule-of-thumb says at least 1% of market cap turning daily is needed for unconstrained sizing. Annual turnover of 46% means the entire float changes hands roughly every 26 months. That is consistent with concentrated insider/founder ownership and limited free float — and it bounds what an external fund can realistically own.

B. Fund-Capacity Table

The reverse-mapping is the table that matters. At a 20% participation rate (active block-builder), the largest fund that can put on a 5% position inside five trading days is roughly $45M AUM; at a 10% participation rate (more typical for a passive accumulator), that drops to $23M AUM. Anything north of $130M AUM cannot meaningfully express ELIX as a portfolio position without staging over multiple weeks or sourcing blocks off-screen.

C. Liquidation Runway

Only the 0.5%-of-market-cap tier (~$2.6M) clears the conventional five-trading-day exit threshold — and even that takes six sessions at an aggressive 20% participation rate. A 1% issuer-level position takes nearly two and a half weeks; a 2% position takes a month at 20% ADV and nearly nine weeks at 10%.

D. Execution Friction

The 60-day median daily price range is 1.65% — tight enough to keep impact costs reasonable on small lots, but it does not change the binding ADV constraint above.

Bottom line on liquidity: the largest size that clears the five-day threshold at a 20% participation rate is roughly $2.3M, or 0.4% of market cap. The more conservative 10%-participation cut sits at $1.1M, or 0.2% of market cap. Liquidity, not the technical setup, is the primary constraint on this name.

Technical Scorecard and Stance

Net technical score: -1 of 6 dimensions. Stance: NEUTRAL on a 3-to-6-month horizon, with a bearish trend overlay and constructive near-term momentum. The setup is a stock that broke its medium-term uptrend in February-March 2026, printed an oversold RSI low at 25, and is now mid-relief-rally — but still trading below its 200-day SMA and showing realised vol at the upper end of its ten-year band. The two levels that resolve the stance are $10.13 and $8.74: a sustained close above $10.13 would reclaim the 200-day average and turn the late-March death cross into a whipsaw, opening a path back toward the $11.86 all-time high; a break below $8.74 loses the 50-day SMA ($9.01) and the post-bounce consolidation floor, opening $7.68 (the 52-week low) as the next reference.

Liquidity is the binding constraint. Even if the tape resolves bullish, only specialist mandates below ~$45M AUM can build a 5% position cleanly. For larger funds, the correct action is watchlist only unless block availability appears, with any build staged over several weeks at a participation rate at or below 10% of ADV.